Alpha-Lipoic Acid: Therapeutic Potential in Diabetic Neuropathies

Victoria Serhiyenko*, Ludmila Serhiyenko, Mychailo Krasnyi and Alexandr Serhiyenko

Department of Endocrinology, Danylo Galytsky Lviv National Medical University, Ukraine

Submission: May 14, 2018; Published: May 30, 2018

*Corresponding author: Victoria Serhiyenko, Department of Endocrinology, Danylo Halytsky Lviv National Medical University, Ukraine, 69, Pekarska str., 79010, Ukraine, Tel: +38-322-76-94-96; Email: 965554@ukr.net; serhiyenkoa@gmail.com

Abstract

Diabetic neuropathy due to nerve damage caused by uncontrolled hyperglycemia is a common and serious complication strongly associated with diabetes mellitus. Its management focuses on long-term durable glycaemic control, multifactorial cardiovascular risk intervention, pathogenesis-oriented therapy. Clinical trials clearly suggest beneficial effects of α-lipoic acid (ALA) consumption on lipid metabolism profile, endothelial activation, its anti-inflammatory, antithrombotic and antiatherosclerotic properties. We reviewed available evidence of the benefits of ALA administration, especially to patients with diabetic neuropathy, diabetic peripheral neuropathy, diabetic cardiovascular autonomic neuropathy, including effects on glucose and lipids metabolism parameters, thrombocyte aggregation state, endothelial function and antioxidant/anti-inflammation properties.

Keywords: Alpha-lipoic acid; Diabetes mellitus; Diabetic neuropathy; Diabetic cardiovascular autonomic neuropathy; Lipids; Inflammation; Platelets; Endothelium; Heart rate variability

Introduction

Diabetes mellitus (DM) is a chronic metabolic disease with a high prevalence worldwide. DM and insulin resistance (IR) are associated with the development of cardiovascular and nervous diseases [1]. The development of these disorders reflects complex pathological processes in which the oxidative stress (OS) caused by reactive oxygen species (ROS) and reactive nitrogen species plays a pivotal role [2,3].

The prevalence of neuropathy in diabetic patients is about 30%, whereas up to 50% of patients will certainly develop neuropathy during the course of the disease [4,5]. The main pathophysiological pathway of diabetic neuropathy (DN) is associated with OS activation. Elevated intracellular levels of glucose lead to advanced glycation end-products formation and polyol pathway activation, resulting in subsequent formation of ROS [6]. Pathogenetic treatment of DN includes: balanced diet and physical activity; optimization of glycaemic control; treatment of dyslipoproteinemia; correction of metabolic abnormalities in myocardium; prevention and treatment of thrombosis; use of aldose reductase inhibitors, γ-linolenic acid, acetyl-L-carnitine, dihomo-γ-linolenic acid, antioxidants, first of all α-lipoic acid (ALA), use of ω-3 and ω-6 polyunsaturated fatty acids, vasodilators, fat-soluble vitamin B1 (benfotiamine), aminoguanidine; substitutive therapy of growth factors and others [3,7].

Discussion

Given the role of OS in diabetic neuropathy, diabetic peripheral neuropathy (DPN), diabetic cardiovascular autonomic neuropathy (CAN) progression, antioxidants such as acetyl-L-carnitine, taurine and ALA have been proven to be effective in preventing or delaying the onset of DPN [5,8-11]. Improvements in glucose disposal were also observed in patients with type 2 diabetes mellitus (T2DM) receiving ALA either i.v. or p.o. [12]. Also other studies findings represent ALA function in improving glycated haemoglobin A1c (HbA1c), lipid peroxidation, antioxidant enzymes and inflammatory markers. ALA has a function in decreasing damages caused by DN and inflammatory markers as a compound with strong antioxidant potential [13-16].

Five randomized double-blind placebo-controlled (RDBPC) trials, the Alpha-Lipoic Acid in Diabetic Neuropathy (ALADIN), Symptoms Of Diabetic Polyneuropathy (SYDNEY), Oral Pilot (ORPIL), SYDNEY 2, and ALADIN III studies, comprising a total of 1160 people were selected. The study populations included individuals ranging in age from 18 to 74yr with T1DM and T2DM. Mean body mass indices ranged from 27.7 to 30.9kg/m². On average, initial HbA1c was <12% and average DM duration ranged from 10.4 to 15.1yr; while that of diabetic sensorimotor
polyneuropathy (DSPN) ranged from 2.8 to 5 yr. The five studies evaluated the effectiveness of ALA on DSPN using three different types of drug administration. Two studies evaluated the role of i.v. ALA compared with placebo. The parenteral treatment was given to separate intervention groups in doses of 100mg, 600, and 1200mg q.d. A total of 14 treatments were given over 3wks in both studies [17,18]. Two of them examined the effects of p.o. ALA administration relative to control patients with DSPN. Oral treatment was given to individual groups at total q.d. of 600 mg, 1200mg, and 1800mg. Duration of treatment ranged from 3 to 5wks [17,19]. One trial included a combination of parenteral and p.o. ALA given sequentially. Combination therapy included schedules of ALA 600mg iv daily for 3wks prior to 1800mg p.o. daily for 6mos and 600mg i.v. daily prior to p.o. placebo for 6mos versus iv placebo treatment followed by p.o. placebo treatment. The total study duration was 7mos [18,20]. Treatment with ALA 600mg i.v. q.d. for 3wks represents a well-tolerated and effective therapy for DSPN. Similarly, an p.o. dose of 600mg q.d. administered for up to 5wks could offer benefits in symptoms and signs of DSPN without significant side effects. Whereas a single study using sequential parenteral and p.o. therapy failed to show a significant effect, the preponderance of evidence supports the effectiveness of ALA in treating the symptoms and signs of DSPN [18]. Benefits of p.o. treatment with ALA were studied in SYDNEY 2. A 5wks trial showed that p.o. treatment with ALA for 5wks improved neuropathic symptoms and deficits in patients with DPN, and an p.o. dose of 600mg once daily provide the optimum risk-to-benefit ratio while effect on electrophysiological parameters was not reported [5].

Two recent meta-analysis evaluate the use of ALA in DN. One of them, included 1.258 diabetic patients treated with 600mg of ALA i.v. for three wks, concluded that pain, numbness and burning decreased significantly with ALA in comparison to placebo. Considering the components of neuropathy impairment score Lower Limb (NIS-LL) an improvement was noted in pin-prick, touch pressure and ankle reflexes. This meta-analysis also pointed out some relevant aspects for conducting future trials to evaluate the benefits of ALA on DN as follows: homogeneity of the studied patients; duration of the trial; end-points with less variability and finally considering the slowing progression of DN the end point must have to exclude the latter and address improvement [21,22]. The other meta-analysis included 653 diabetic patients treated with different doses of ALA p.o. (two studies) or i.v. (two studies) for three (3 studies) to 5wks (one study) concluded that total symptoms score (TSS) decreased significantly but only in the i.v. study the TSS decrease more than 30% which was considered to be clinically significant. Recently, a non-randomized, open-label and prospective study has shown an improvement in pain and electroneurographic parameters, mainly in sensory nerve conduction, among 50 patients with DSPN treated with a new p.o. formulation combining ALA 400mg/g.d. and superoxide dismutase 140IU/g.d. for four mos [22-24].

The results of meta-analysis provide evidence that treatment with ALA (300-600mg/day i.v. for 2-4 wks) is safe and that the treatment can significantly improve both nerve conduction velocity and neuropathic symptoms [25]. Finally, it is important to mention the NATHAN 1 Trial (Neurological Assessment of Thiocotic Acid in Diabetic Neuropathy), a multicenter study which used 600mg of ALA q.d. for four yr with NIS-LL + seven neurophysiologic tests as primary outcome. In this study after a four-yr treatment with ALA in mild-to-moderate DSPN did not influence the primary composite end point but resulted in a significant clinical improvement and prevention of progression of neuropathic impairments. As the primary composite end point did not deteriorate in placebo-treated subjects, secondary prevention of its progression by ALA according to the trial design was not feasible. All these latter studies concluded that the usual dose of 600mg is safe and well tolerated with mainly dose dependent gastrointestinal adverse events. Moreover, with one exception (sural latency), all these studies did observe improvement in electrophysiological tests [22,26].

A RDBPC study with 30 patients with T2DM evaluated glycaemic control and endothelial responses to i.v. acetylcholine (endothelium-dependent) and nitrate (endothelium-independent) in order to evaluate the forearm blood flow before and after the use of 600mg of ALA i.v. for three wks. A decrease in HbA1c, total cholesterol (TC) and triglycerides (TG) levels were observed in both groups. However only the ALA treated patients showed an improvement in the endothelium dependent vasodilation [22,27].

The Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) clinical trial has examined ALA as a potential remedy for endothelial dysfunction. This trial was a RDBPC study comparing ALA to irbesartan, an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Results showed that the p.o. administration of ALA (300mg/q.d. for 4wks) and/or irbesartan (150mg/q.d. for 4wks) to 15 patients with metabolic syndrome (MetS) in each group improved endothelial-dependent flow-mediated vasodilation, which was measured by using the noninvasive brachial artery reactivity test [12,28]. The ISLAND trial showed a 15% significant decrease in serum interleukin (IL)-6 levels following 4wks of supplementation with ALA (300mg/day). This finding may prove the anti-inflammatory effects of ALA, as IL-6 is a recognized marker of inflammation in coronary atherosclerotic plaques, and also regulates the expression of other inflammatory cytokines, such as IL-1 and tumor necrosis factor-alpha. However, the body of evidence is currently too limited and could not be considered as conclusive [12,28].

A RDBPC study (DEKAN) was conducted in patients with T2DM with CAN using 800mg of ALA q.d. for 16wks. Cardiovascular autonomic tests (CART’s) and heart rate variability (HRV) were evaluated before and after treatment. The intervention with ALA resulted in improvement of some HRV parameters: root mean square successive difference (RMSSD) and power spectrum in

low frequency band (LF). No difference in overall symptoms was observed [29].

We have carried out two studies to analyze the effectiveness of ALA. In the first one we have analyzed the effectiveness of ALA on activity of acetylcholinesterase (ACE) in erythrocytes membrane, superoxide dismutase (SOD), glutathione peroxidase (GPO) and catalase (CAT) in RBC’s, osmotic stability, levels of Na⁺ and K⁺ in erythrocytes, TC, low (LDL-C), and high density lipoprotein-cholesterol (HDL-C), TG in T2DM patients with CAN. 67 patients were allocated in two treatment groups. Thioctic acid was administered i.v. at a q.d. dose of 600mg, during 2wks, and single q.d. of 600mg p.o during the next 2mos. It was defined that ACE activity increases in RBC’s membrane what testifies about the reconstruction of membranes, penetration increasing of them, especially for Na⁺ and K⁺ (confirmed by increased levels of Na⁺ and K⁺ in erythrocytes). High level of TC, LDL-C, TG (p <0.05) and depressed enzymes activity were diagnosed in all of them. At the end of 2mos TG and LDL-C levels were decreased more significantly in patients from treatment group. Also, we observed more significantly improve of CART’s. ALA in dose of 600mg q.d. during 2mos increases activity of SOD (p <0.001), GPO (p<0.001) and CAT (p <0.05), osmotic stability in RBC’s, what testify about the increase of antioxidant defense and stabilization of lipids bilayer in erythrocytes membrane. So, ALA promotes to decrease the activity of ACE in RBC’s membrane, what testify about the tendention to normalize penetration of membranes, especially for Na⁺ and K⁺ [30,31]. To the second one were included 49 patients with T2DM and CAN. All patients were randomized to receive either a daily i.v. (2wks) and then p.o. dose of 600mg ALA (n=32) or placebo (n=17) during 2mos. CAN assessed by to receive either a daily i.v. (2wks) and then p.o. dose of 600mg ALA (n=32) or placebo (n=17) during 2mos. CAN assessed by

The combination of ALA and vitamin B complex was effective in improving nerve function parallel to symptoms improvement [5]. There was a significant reduction after 12wks of supplementation in vitamin B complex plus ALA group using the Michigan Neuropathy Screening Instrument (MNSI) questionnaire and not in vitamin B complex group. Study demonstrated that 12 out of 16 patients in vitamin B complex plus ALA group showed improvement in at least one property measured compared with only 6 out of 16 in vitamin B complex group. The influence of the combination on the progression of DM with regards to IR and lipid profile showed no advantage over vitamin B complex alone [5]. ALA has been used in 94 patients with T2DM in a RDBPC study which has tested three antioxidants for three mos in association with metformin and glimeperide: ALA, 300mg/q.d., ecosapentanoic acid, 180mg plus docohexaenoic acid, 120mg/ q.d. omega 3 fatty acids and vitamin E 400mg/q.d. Although an improvement in HbA1c weight and waist have been observed with ALA, omega 3 fatty acids gave the better results concerning weight loss and glycaemic control [22].

Conclusion

ALA has been widely prescribed drug for treatment and prevention of chronic diabetic complications since it affects the main pathogenesis links. The many unique properties of ALA, namely prevention of beta-cell destruction, enhancement of glucose uptake, antioxidant effects, inhibition of glycation reactions, restoration of vitamins levels, improvement of neurons function and conduction has been shown in a number of experimental and clinical trials. However, further randomized, double-blind, placebo-controlled trials of larger scale and longer duration are necessary to strengthen existing data and provide greater insight into the long-term efficacy of ALA.
Conflict of Interest

The authors have declared no financial/commercial conflict of interest.

References


